PluroGen Therapeutics, Inc.
503 Broadleaf Way
Charlottesville, VA 22911
Tel: 443 994 0101
Fax: 410 990 9817
www.plurogen.com
503 Broadleaf Way
Charlottesville, VA 22911
Tel: 443 994 0101
Fax: 410 990 9817
www.plurogen.com
| News Release |
FOR IMMEDIATE RELEASE Contact: Neal G. Koller
President & CEO
08 July 2009 Board of Directors
443 994 0101
PLUROGEN RECEIVES PRELIMINARY OPINION OF APPROVABLE-FOR-SALE IN EUROPE
FOR LEAD BURN AND CHRONIC WOUND GEL
(Charlottesville, VA, 8 July 2009) – PluroGen Therapeutics, Inc. is pleased to announce that the initial
European Health Authority review of our medical device marketing application for our lead burn and chronic
wound topical gel, PluroGel® Silver Sulfadiazine, has resulted in a preliminary opinion of approvable-for-
sale in Europe. The next steps in the European approval process are formal submission of the medical
device marketing application and manufacturing inspection by the European approving body. Pending
approval of the additional steps, PluroGen could be selling PluroGel® Silver Sulfadiazine in Europe by the
end of the year.
Neal G. Koller, President & CEO of PluroGen, commented on the European Health Authority’s Approvability
Opinion that “This is the Company’s most significant milestone so far achieved in 2009 as it clears the way
into the market for our lead topical product for burns and chronic wounds. Even more, it will extend the
PluroGel® product line as this new Silver Sulfadiazine product will compliment PluroGel® products already
being sold - as well as those in development - with our European partner Welcare Industries. This is a
very exciting and extremely important achievement for PluroGen.”
About PluroGen Therapeutics, Inc.
PluroGen is a skin care and wound healing company commercializing our core patent-protected gel
technology platform that provides superior and differentiated physical, bio-impact and multi-function
benefits. Our multiple technology platforms are configurable to deliver drug and non-drug compounds as
protected and advanced therapeutic and topical products for simple and complex skin care, burn and
wound healing. PluroGen’s product pipeline targets improved, protected therapies for the 6 areas of
treatment in tissue management and healing (cleansing, infection, pain, inflammation, tissue salvage,
tissue regeneration).
PluroGen’s first gels, PluroGel® and ActiviGel™, are being used initially in skin and wound cleansing
products, for personal skin care products, for PluroGel® Burn and Chronic Wound Barrier Gels and Barrier
Dressings and for a topical antibiotic. PluroGel® / ActiviGel™ technology is currently in routine use at the
University of Virginia Medical Center, having shown superior results on more than 2,000 patients in two
different patient populations, severe burns and chronic wounds. The PluroGen management and
operational teams, Boards and Principal Investigators are recognized global clinical and commercial
leaders in PluroGen’s target markets of burn and wound care and in the life sciences industry.
For more information about PluroGen Therapeutics, Inc., visit the Company’s web site at www.plurogen.
com.
Statements included in this press release that are not historical in nature are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that
forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to
differ materially and which are identified from time to time in the Company’s reports filed with the U.S.
Securities and Exchange Commission. PluroGen Therapeutics, Inc. claims the protection of the Safe Harbor for
forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Information included on PluroGen Therapeutics, Inc website is not incorporated herein by reference or otherwise.
© PluroGen Therapeutics, Inc. 2009
President & CEO
08 July 2009 Board of Directors
443 994 0101
PLUROGEN RECEIVES PRELIMINARY OPINION OF APPROVABLE-FOR-SALE IN EUROPE
FOR LEAD BURN AND CHRONIC WOUND GEL
(Charlottesville, VA, 8 July 2009) – PluroGen Therapeutics, Inc. is pleased to announce that the initial
European Health Authority review of our medical device marketing application for our lead burn and chronic
wound topical gel, PluroGel® Silver Sulfadiazine, has resulted in a preliminary opinion of approvable-for-
sale in Europe. The next steps in the European approval process are formal submission of the medical
device marketing application and manufacturing inspection by the European approving body. Pending
approval of the additional steps, PluroGen could be selling PluroGel® Silver Sulfadiazine in Europe by the
end of the year.
Neal G. Koller, President & CEO of PluroGen, commented on the European Health Authority’s Approvability
Opinion that “This is the Company’s most significant milestone so far achieved in 2009 as it clears the way
into the market for our lead topical product for burns and chronic wounds. Even more, it will extend the
PluroGel® product line as this new Silver Sulfadiazine product will compliment PluroGel® products already
being sold - as well as those in development - with our European partner Welcare Industries. This is a
very exciting and extremely important achievement for PluroGen.”
About PluroGen Therapeutics, Inc.
PluroGen is a skin care and wound healing company commercializing our core patent-protected gel
technology platform that provides superior and differentiated physical, bio-impact and multi-function
benefits. Our multiple technology platforms are configurable to deliver drug and non-drug compounds as
protected and advanced therapeutic and topical products for simple and complex skin care, burn and
wound healing. PluroGen’s product pipeline targets improved, protected therapies for the 6 areas of
treatment in tissue management and healing (cleansing, infection, pain, inflammation, tissue salvage,
tissue regeneration).
PluroGen’s first gels, PluroGel® and ActiviGel™, are being used initially in skin and wound cleansing
products, for personal skin care products, for PluroGel® Burn and Chronic Wound Barrier Gels and Barrier
Dressings and for a topical antibiotic. PluroGel® / ActiviGel™ technology is currently in routine use at the
University of Virginia Medical Center, having shown superior results on more than 2,000 patients in two
different patient populations, severe burns and chronic wounds. The PluroGen management and
operational teams, Boards and Principal Investigators are recognized global clinical and commercial
leaders in PluroGen’s target markets of burn and wound care and in the life sciences industry.
For more information about PluroGen Therapeutics, Inc., visit the Company’s web site at www.plurogen.
com.
Statements included in this press release that are not historical in nature are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that
forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to
differ materially and which are identified from time to time in the Company’s reports filed with the U.S.
Securities and Exchange Commission. PluroGen Therapeutics, Inc. claims the protection of the Safe Harbor for
forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Information included on PluroGen Therapeutics, Inc website is not incorporated herein by reference or otherwise.
© PluroGen Therapeutics, Inc. 2009